Proposed Re-evaluation Decision PRVD2022-09, Bacillus amyloliquefaciens strain MBI600 and Bacillus subtilis strain QST 713 and the Associated End-use Products (English, HTML)

Proposed Re-evaluation Decision PRVD2022-09, Bacillus amyloliquefaciens strain MBI600 and Bacillus subtilis strain QST 713 and the Associated End-use Products: English HTML file. From Health Canada, updated May 2023. View metadata, licence and the direct download on CanQuery.

Format
HTML
Access
Original download only
Publisher-reported update
2023-05-31

Bacillus amyloliquefaciens strain MBI600 is a naturally occurring bacteria which suppresses plant diseases by preventing growth of pathogenic fungi through displacement and direct antagonistic action. All products containing Bacillus amyloliquefaciens strain MBI600 registered in Canada are subject to this proposed re-evaluation decision. The final re-evaluation decision will be published taking into consideration the comments and information received during the consultation period.

Access original file

Data overview

Formats
HTML
File languages
English
Available actions
Access original file

Official sources and licences

Related open data